PRINCETON, N.J.–(BUSINESS WIRE) May 30, 2023 — Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for repotrectinib, a next-generation tyrosine kinase inhibitor (TKI), for the treatment of patients with ROS1-positive locally advanced or metastatic non-small cell…Read More
US Food and Drug Administration Accepts for Priority Review Bristol Myers Squibbs Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1Positive NonSmall Cell Lung Cancer
